US Long-Acting Bronchodilator Market Growth, Size, Share and Industry Report to 2019-2025


Posted February 27, 2020 by larebomrglobal

The US long-acting bronchodilator market is anticipated to grow at a substantial rate of 1.7% during the forecast period.

 
The US long-acting bronchodilator market is anticipated to grow at a substantial rate of 1.7% during the forecast period. The growth of the market of long-acting bronchodilator devices in the US is mainly driven by factors that include the growing prevalence of chronic diseases such as asthma, diabetes, respiratory lung diseases and so on. Asthma is chronic inflammation of the lung airways that causes breathlessness and coughing. The number of people with asthma grows every year in the US. According to CDC 2017, there were around 26 million asthma patients in the US, among which, nearly 18.9 million were adults and 7.1 million were children. Moreover, the prevalence of asthma in children is nearly 9.4% which is higher than that of adults accounting to around 7.7%, and higher in females nearly 9.2% than in males accounting to 7% of total asthma patients. This is one of the primary reasons for the high growth rate of the market within the country.

Request a Free Sample of our Report on US Long-Acting Bronchodilator Market https://www.omrglobal.com/request-sample/uk-long-acting-bronchodilator-market

The US long-acting bronchodilator market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, nasal, parenteral, and inhalation. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the country. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed. The homecare segment is estimated to share significant market share in the market.

A full Report of US Long-Acting Bronchodilator Market is Available at: https://www.omrglobal.com/industry-reports/us-long-acting-bronchodilator-market

US Long-Acting Bronchodilator Market Segmentation

By Route of Administration

• Oral
• Nasal
• Parenteral
• Inhalation

By Application

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)

By End-User

• Homecare
• Hospitals and Clinics

Company Profiles

• Adamis Pharmaceuticals Corp.
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline PLC
• Novartis AG
• ResMed Corp.
• Pulmatrix Inc.
• Savara, Inc.
• Sunovion Pharmaceuticals
• Teva Pharmaceuticals Industries Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/us-long-acting-bronchodilator-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Mr. Anurag Tiwari
Phone 07803040404
Business Address 305, Commerce House, 308, 11 Bungalow Colony, New Palasia, Indore, Madhya Pradesh
Country India
Categories Business , Industry , News
Tags US Long-Acting Bronchodilator Market , US Long-Acting Bronchodilator Market Growth , US Long-Acting Bronchodilator Market Trends
Last Updated February 27, 2020